Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.164 | 0.151 | 0.177 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.195 | 0.181 | 0.209 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0312 | -0.0502 | -0.0122 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.84 | 0.755 | 0.934 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.808 | 0.71 | 0.92 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Dapa 10 mg than on Placebo | 32 | 19.9 | 81.7 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Dapa 10 mg | Dapagliflozin 10 mg tablets administered once daily per oral use | 512 | 3,131 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use | 610 | 3,132 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. | ClinicalTrials.gov |
| Description | Dual primary efficacy~Primary endpoint analysed in all patients randomised (Full analysis set).~The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date. | ClinicalTrials.gov |
| Time frame | Up to 42.1 months | ClinicalTrials.gov |
| Population | Full analysis set | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. | ClinicalTrials.gov |
| NCT number | NCT03619213 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Heart Failure With Preserved Ejection Fraction | ClinicalTrials.gov |
| Interventions | Dapagliflozin, Placebo | ClinicalTrials.gov |
| Lead sponsor | AstraZeneca | ClinicalTrials.gov |
| Results first posted | 2023-07-11 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03619213?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.